Jingjing Yu
Affiliations: | 2007 | Biology | Rensselaer Polytechnic Institute, Troy, NY, United States |
Google:
"Jingjing Yu"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Robert J. Linhardt | grad student | 2007 | RPI | |
| ((Understanding the Mechanism of Polyphenolic Inhibition on Human Vascular NADPH Oxidase)) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| McFeely SJ, Ritchie TK, Yu J, et al. (2020) Inhibitors of Organic Anion-Transporting Polypeptides 1B1 and 1B3: Clinical Relevance and Regulatory Perspective. Journal of Clinical Pharmacology |
| Yu J, Ragueneau-Majlessi I. (2020) In vitro-to-in vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the U.S. Food and Drug Administration in 2018. Clinical and Translational Science |
| Yu J, Petrie I, Ragueneau-Majlessi I. (2020) P87 - Main mechanisms of pharmacokinetic drug-drug interactions triggering label recommendations for drugs approved by the food and drug administration in 2018 Drug Metabolism and Pharmacokinetics. 35 |
| McFeely SJ, Yu J, Zhao P, et al. (2019) Drug-Drug Interactions of Infectious Disease Treatments in Low Income Countries: A Neglected Topic? Clinical Pharmacology and Therapeutics |
| McFeely SJ, Ritchie TK, Yu J, et al. (2019) Identification and Evaluation of Clinical Substrates of Organic Anion Transporting Polypeptides 1B1 and 1B3. Clinical and Translational Science |
| Yu J, Petrie ID, Levy RH, et al. (2018) Mechanisms and Clinical Significance of Pharmacokinetic-based Drug-drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017. Drug Metabolism and Disposition: the Biological Fate of Chemicals |
| Yu J, Zhou Z, Tay-Sontheimer J, et al. (2018) Risk of Clinically Relevant Pharmacokinetic-based Drug-drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016. Drug Metabolism and Disposition: the Biological Fate of Chemicals |
| Yu J, Ragueneau-Majlessi I. (2018) Understanding the risk of clinically significant pharmacokinetic-based drug–drug interactions with drugs newly approved by the US FDA – A review of recent new drug applications (2013–2016) Drug Metabolism and Pharmacokinetics. 33 |
| Yu J, Zhou Z, Tay-Sontheimer J, et al. (2017) Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Pre-clinical and Clinical Findings. Journal of Pharmaceutical Sciences |
| Yu J, Zhou Z, Owens KH, et al. (2016) What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the U.S. FDA in 2015. Drug Metabolism and Disposition: the Biological Fate of Chemicals |